{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:31:24Z","timestamp":1793881884488,"version":"4.7.0"},"reference-count":68,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The immunosuppression inherent to chronic lymphocytic leukemia (CLL) is the most frequent cause of morbidity and mortality associated with this pathology. Both the innate and adaptive immune responses exhibit marked functional alterations, with a bias towards a tolerant environment that favors the spread of the disease. This condition is reflected in increased risk of infections, immune-mediated cytopenias, and associated second malignancies. Knowledge of these alterations, both in the molecular pathways that modulate T cell activity in CLL (the T lymphocyte cytotoxic antigen-4 (CTLA-4) axis and programmed cell death 1 (PD-1)) and at the T cell immunoreceptor level, could be of interest as therapeutic targets in CLL. In this review, we will analyze the main consequences of this dysfunction and its management strategies.<\/jats:p>","DOI":"10.3390\/cancers18091323","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:01:24Z","timestamp":1776848484000},"page":"1323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Implications of Immune Dysfunction in Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1448-8601","authenticated-orcid":false,"given":"Luis Miguel","family":"Ju\u00e1rez-Salcedo","sequence":"first","affiliation":[{"name":"Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3561-3758","authenticated-orcid":false,"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[{"name":"Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain"},{"name":"Human Medicine Department, Autonoma University of Madrid, 28049 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic Lymphocytic Leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","article-title":"Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions","volume":"131","author":"Puente","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: A target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000533234","article-title":"Immune Dysfunction and Infection\u2014Interaction between CLL and Treatment: A Reflection on Current Treatment Paradigms and Unmet Needs","volume":"147","author":"Gargiulo","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2016.362","article-title":"Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: High-throughput immunoprofiling supports selection by shared antigenic elements","volume":"31","author":"Vardi","year":"2017","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3324\/haematol.2012.073080","article-title":"The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation","volume":"98","author":"Maffei","year":"2013","journal-title":"Haematologica"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.seminhematol.2014.05.006","article-title":"Immunomodulation and immune reconstitution in chronic lymphocytic leukemia","volume":"51","author":"Riches","year":"2014","journal-title":"Semin. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","article-title":"The hypoxic tumour microenvironment","volume":"7","author":"Petrova","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2005-05-1795","article-title":"Tumor-derived lactic acid modulates dendritic cell activation and antigen expression","volume":"107","author":"Gottfried","year":"2006","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell\u2013derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha","volume":"106","author":"Nishio","year":"2005","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Arruga, F., Gyau, B.B., Iannello, A., Vitale, N., Vaisitti, T., and Deaglio, S. (2020). Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051825"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/asheducation-2007.1.332","article-title":"Management of infectious complications in patients with chronic lymphocytic leukemia","volume":"2007","author":"Morrison","year":"2007","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ejh.70065","article-title":"Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies","volume":"116","author":"Martino","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_19","first-page":"321","article-title":"Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively","volume":"40","author":"Moreno","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1182\/bloodadvances.2024013073","article-title":"IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: Real-world evidence","volume":"8","author":"Soumerai","year":"2024","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: Pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1093\/oncolo\/oyac032","article-title":"Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination","volume":"27","author":"Guven","year":"2022","journal-title":"Oncologist"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/bloodadvances.2021006215","article-title":"Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia","volume":"6","author":"Bagacean","year":"2022","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: A national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1038\/s41375-021-01362-7","article-title":"Publisher Correction: T cells in chronic lymphocytic leukemia: Guardians or drivers of disease?","volume":"35","author":"Roessner","year":"2021","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/17474086.2025.2523552","article-title":"Incidence, prevention and management of severe infections in patients undergoing therapy for chronic lymphocytic leukemia","volume":"18","author":"Bevilacqua","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"McManus, S., Khare, P., and Bertilaccio, M.T.S. (2025). Neutrophils unveiled in chronic lymphocytic leukemia. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1609754"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.blre.2018.03.004","article-title":"Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections","volume":"32","author":"Hilal","year":"2018","journal-title":"Blood Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies","volume":"32","author":"Teh","year":"2018","journal-title":"Blood Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1007\/s00277-025-06502-y","article-title":"Infectious complications in CLL\/SLL patients receiving Bruton\u2019s Tyrosine Kinase inhibitors\u2014Systematic review and meta-analysis of randomized controlled trials","volume":"104","author":"Buchrits","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed Duration of Venetoclax-Rituximab in Relapsed\/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","volume":"37","author":"Kater","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_33","first-page":"1084","article-title":"Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia","volume":"394","author":"Stumpf","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Ram\u00f3n, S., Dhalla, F., and Chapel, H. (2016). Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00317"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults","volume":"330","author":"Zhou","year":"2023","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-8278(88)80032-1","article-title":"Persistence of specific antibodies after hepatitis B vaccination","volume":"6","author":"Jilg","year":"1988","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.hoc.2025.05.002","article-title":"Autoimmune Cytopenias in Chronic Lymphocytic Leukemia","volume":"39","author":"Vitale","year":"2025","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.beha.2010.01.004","article-title":"Autoimmune complications in chronic lymphocytic leukaemia (CLL)","volume":"23","author":"Zent","year":"2010","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Vitale, C., Montalbano, M.C., Salvetti, C., Boccellato, E., Griggio, V., Boccadoro, M., and Coscia, M. (2020). Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. Cancers, 12.","DOI":"10.3390\/cancers12020282"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2008.07086.x","article-title":"The prognostic significance of cytopenia in chronic lymphocytic leukaemia\/small lymphocytic lymphoma","volume":"141","author":"Zent","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08707.x","article-title":"Autoimmune cytopenia in chronic lymphocytic leukaemia: Diagnosis and treatment","volume":"154","author":"Hodgson","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.3109\/10428194.2014.986479","article-title":"Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias","volume":"56","author":"Lad","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"Barcellini","year":"2020","journal-title":"Blood Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/17474086.2023.2216930","article-title":"Strategies to overcome the diagnostic challenges of autoimmune hemolytic anemias","volume":"16","author":"Barcellini","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1182\/bloodadvances.2023012541","article-title":"The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia","volume":"8","author":"Neunert","year":"2024","journal-title":"Blood Adv."},{"key":"ref_48","first-page":"80","article-title":"Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia","volume":"25","author":"Diehl","year":"1998","journal-title":"Semin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood.V99.3.1092","article-title":"Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia","volume":"99","author":"Ghazal","year":"2002","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood.2020008201","article-title":"Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs","volume":"137","author":"Vitale","year":"2021","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/bjh.15545","article-title":"Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre","volume":"183","author":"Hampel","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/1097-0142(20011015)92:8<2016::AID-CNCR1539>3.0.CO;2-E","article-title":"Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia","volume":"92","author":"Cortes","year":"2001","journal-title":"Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-019-0237-1","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jha2.366","article-title":"Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter\u2019s syndrome","volume":"3","author":"Shen","year":"2022","journal-title":"EJHaem"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.leukres.2018.07.003","article-title":"Management of melanoma in patients with chronic lymphocytic leukemia","volume":"71","author":"Archibald","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/jnci\/djy052","article-title":"Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival","volume":"110","author":"Herr","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood.V98.6.1979","article-title":"Solid tumors after chronic lymphocytic leukemia","volume":"98","author":"Hisada","year":"2001","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/10428194.2019.1709830","article-title":"Multiple B cell malignancies in patients with chronic lymphocytic leukemia: Epidemiology, pathology, and clinical implications","volume":"61","author":"Parikh","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.22672","article-title":"Risk of second cancer after chronic lymphocytic leukemia","volume":"121","author":"Rosendahl","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1365-2230.1999.00480.x","article-title":"Multiple basal cell carcinomas in a patient with acute myeloid leukaemia and chronic lymphocytic leukaemia","volume":"24","author":"Ramsay","year":"1999","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/10428190310001612939","article-title":"Veterans with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death","volume":"45","author":"Kyasa","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41375-024-02492-4","article-title":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","volume":"39","author":"Hampel","year":"2025","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00262-008-0591-5","article-title":"Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells","volume":"58","author":"Liu","year":"2009","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1196\/annals.1361.044","article-title":"IL-10 and the cytokine network in the pathogenesis of human autoimmune hemolytic anemia","volume":"1051","author":"Fagiolo","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"175","DOI":"10.6004\/jnccn.2024.0018","article-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Wierda","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:24:18Z","timestamp":1776849858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/9\/1323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":68,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cancers18091323"],"URL":"https:\/\/doi.org\/10.3390\/cancers18091323","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]}}}